Skip to main content

Edwards Lifesciences Corp Value Stock - Dividend - Research Selection

Edwards lifesciences

ISIN: US28176E1082 , WKN: 936853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Sapien valve performs equally well for small and large aortic annuli, Edwards finds

2024-06-06
The analysis adds to a debate about the effectiveness of Edwards vs. Medtronic TAVR devices in patients with small aortic annuli, a fibrous ring around the heart’s valve.

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Jazz Pharmaceuticals (JAZZ) and Neurocrine (NBIX)

2024-06-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Edwards Lifesciences Hold Rating: Strategic Divestiture Amid Growth Prospects and Caution

2024-06-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

TD Cowen Sticks to Their Buy Rating for Edwards Lifesciences (EW)

2024-06-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite

2024-06-05
BD's (BDX) latest agreement is likely to unlock new future value-creation opportunities and expand its portfolio of smart connected care solutions.

Five-Year Data Show Excellent Outcomes for Female and Small Annulus Patients With Edwards TAVR

2024-06-05
NEW YORK, June 05, 2024--Edwards Lifesciences (NYSE: EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through five-year follow up of more than 1,300 low and intermediate risk SAPIEN 3 valve patients there were excellent clinical outcomes and valve durability irrespective of the patient’s annulus size or sex. These data were presented during the late-breaking clinical

Edwards Lifesciences reports results from data analysis from PARTNER trials

2024-06-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

The most crowded longs and shorts in U.S. Med-Tech for May - UBS

2024-06-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

3 Best Healthcare Stocks to Buy in June 2024, as per Analysts

2024-06-05
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Edwards Lifesciences (NYSE:EW) Knows How To Allocate Capital

2024-06-04
What are the early trends we should look for to identify a stock that could multiply in value over the long term...